These Funds Are Suddenly Outperforming Themselves
Only a handful of funds are seeing their market edge accelerate this sharply; here are the ones leading the pack.
A fund’s three-year record can hide a powerful, recent shift in performance. This analysis pinpoints funds whose current one-year alpha is surging far above its own longer-term average. That matters because it can be an early signal that a fund’s strategy is clicking in the current market, long before its multi-year numbers reflect the change.
A New Class Of Leaders Emerges.
Out of 131 US equity funds, just 20 clear this demanding bar today. The State Street SPDR S&P Biotech ETF (XBI) provides the clearest example, with a current performance edge that has rocketed past its own lackluster history. The table below shows the top five funds from this select group, ranked by the scale of their recent alpha improvement.
| Ticker | Fund | AUM | 1Y Alpha | Alpha Change | Beta | P/E vs Hist |
|---|---|---|---|---|---|---|
| XBI | State Street SPDR S&P Biotech ETF | $11.1B | +60% | +71% | 0.95 | +11.4% |
| XOP | State Street SPDR S&P Oil & Gas Exploration & Production ETF | $3.3B | +46% | +57% | 1.00 | +34% |
| FXN | First Trust Energy AlphaDEX Fund | $376M | +41% | +51% | 0.92 | +60% |
| SOXX | iShares Semiconductor ETF | $47.6B | +46% | +45% | 1.60 | +28% |
| IBB | iShares Biotechnology ETF | $9.4B | +34% | +45% | 0.80 | -1.6% |
Of the 20 funds that qualify, the table shows the top five by alpha change versus its own 3-year average.
XBI’s Alpha Just Flipped From Negative To Positive
The State Street SPDR S&P Biotech ETF (XBI) spent years trailing the market, posting a 3-year alpha of -11.3% a year. But its recent performance tells a different story, with its alpha over the past year soaring to +60%. That sharp turnaround has pushed its valuation 11% above its own historical norm, a sign that other investors are taking notice. While XBI is diversified across many names, it’s worth understanding how concentration works in biotech funds, as some portfolios in this sector are less diversified than they appear.
XOP Delivers A Similar Turnaround With More Risk
The State Street SPDR S&P Oil & Gas Exploration & Production ETF (XOP) shows a similar pattern, with its 1-year alpha of +46% erasing a difficult 3-year average of -11.2% a year. It gets there with a different risk profile, however. XOP moves almost in lockstep with the S&P 500, carrying a beta of 1.00, which means it offers little cushion in a market downturn. Its holdings are also more concentrated, with its ten largest holdings making up 29% of the fund.
The Catch In The Comeback
The risk with a one-year alpha surge is that it can be just that: one good year. For a fund like the iShares Semiconductor ETF (SOXX), whose beta is a high 1.60, a market reversal could quickly unwind its recent gains. This list is a starting point for research, not a shopping list. Before acting, check if a fund’s improving alpha is matched by a valuation you can live with and a level of market risk that fits your portfolio.
Want To Run A Different Screen?
This is one screen among many, tuned to a single question. If what you care about is a different angle – momentum in a sector, income without the decay, skill without the leverage – the same underlying data answers those too, and it can score any fund you already hold on the exact measures above.
Our ETF Valuation and Performance Scorecard puts every one of these measures – alpha, beta, Sharpe ratio, valuation versus its own history, cost, and concentration – side by side for every major US equity ETF. Run this exact check on any fund you own; it takes seconds, and the result is often not what the fund’s marketing suggests.
You Just Saw Inside One Fund, Now Check The Rest
You have just seen exactly what sits inside one holding, and the same question applies to everything else you own. How much damage any single position could do to your net worth is a question with a precise answer. The Trefis Wealth team computes it for investors professionally, with the same rules-based systematic discipline that runs our High Quality Portfolio. Request a free vulnerability audit of your biggest positions.